{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:07Z","timestamp":1792271947197,"version":"4.4.0"},"reference-count":147,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2018,5,4]]},"DOI":"10.1080\/21645515.2018.1451810","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T16:39:33Z","timestamp":1521131973000},"page":"1146-1160","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":81,"title":["Progress toward the global control of\n                    <i>Neisseria meningitidis<\/i>\n                    : 21st century vaccines, current guidelines, and challenges for future vaccine development"],"prefix":"10.1080","volume":"14","author":[{"given":"A. W.","family":"Dretler","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. G.","family":"Rouphael","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Stephens","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441807"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-346-2_1"},{"key":"e_1_3_3_5_1","article-title":"Initiative for Vaccine Research (IVR)","author":"WHO","unstructured":"WHO. Initiative for Vaccine Research (IVR). Meningococcal Disease.","journal-title":"Meningococcal Disease"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(99)90106-2"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ597"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix993"},{"key":"e_1_3_3_9_1","unstructured":"CDC. Meningococcal Disease: Technical and Clinical information. 2017. https:\/\/www.cdc.gov\/meningococcal\/clinical-info.html."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.007"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.055"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30301-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.10.022"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.04.007"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/2.1.5"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne J","year":"1987","unstructured":"Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol (Baltimore, Md: 1950). 1987;138:4402\u20137.","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1128\/iai.65.11.4436-4444.1997","article-title":"Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose","volume":"65","author":"Estabrook MM","year":"1997","unstructured":"Estabrook MM, Griffiss JM, Jarvis GA. Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun. 1997;65:4436\u201344. PMID:9353017.","journal-title":"Infect Immun."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072577"},{"key":"e_1_3_3_19_1","first-page":"733","article-title":"Serogroup B meningococcal vaccines","volume":"7","author":"Zimmer SM","year":"2006","unstructured":"Zimmer SM, Stephens DS. Serogroup B meningococcal vaccines. Curr Opin Investig Drugs (London, England: 2000). 2006;7:733\u20139.","journal-title":"Curr Opin Investig Drugs (London, England: 2000)"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2006.00057.x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.014"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.01.004"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu601"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.070"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1327"},{"key":"e_1_3_3_26_1","first-page":"68","article-title":"Immunoglobulin deficiencies and meningococcal disease","volume":"57","author":"Castagliuolo PP","year":"1986","unstructured":"Castagliuolo PP, Nisini R, Quinti I, Fattorossi A, D'Amelio R. Immunoglobulin deficiencies and meningococcal disease. Ann Allergy. 1986;57:68\u201370. PMID:3729084.","journal-title":"Ann Allergy"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-12-199512150-00007"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199710000-00015"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450100061026"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.040"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/18.Supplement_A.25"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0910.030182"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix438"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.9.4811-4814.2005"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/B978-0-12-369408-9.00053-6","volume-title":"Vaccines for biodefense and emerging and neglected diseases","author":"Rouphael NG","year":"2009","unstructured":"Rouphael NG, Zimmer SM, Stephens DS. Chapter 53 \u2013 Neisseria meningitidis A2 \u2013 Barrett, Edited by Alan D. T. In: Stanberry LR, ed. Vaccines for biodefense and emerging and neglected diseases. London: Academic Press;2009. p. 1061\u201379."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1086\/322587"},{"key":"e_1_3_3_38_1","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn AC","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1\u201328. PMID:23515099.","journal-title":"MMWR Recomm Rep."},{"key":"e_1_3_3_39_1","unstructured":"Enhanced Meningococcal Disease Surveillance Report 2015. CDC 2017."},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1212055"},{"key":"e_1_3_3_41_1","volume-title":"14th Congress of the EMGM","author":"14th Congress of the EMGM","year":"2017","unstructured":"14th Congress of the EMGM. 14th Congress of the EMGM, European Meningococcal and Haemophilus Disease Society. Prague, Czech Republic; 2017."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2006.00053.x"},{"key":"e_1_3_3_43_1","unstructured":"CDC. Meningococcal disease: surveillance. 2017."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00267-4"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1912.04270080209011"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1367"},{"key":"e_1_3_3_47_1","first-page":"279","article-title":"Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969\u201370","volume":"45","author":"Gold R","year":"1971","unstructured":"Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969\u201370. Bull World Health Organization 1971;45:279\u201382.","journal-title":"Bull World Health Organization"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165-Supplement_1-S49"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1258308"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.083"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/527401"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.010"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2013.11.012"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.10.005"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2461"},{"key":"e_1_3_3_57_1","first-page":"24","article-title":"Recent progress in the prevention of serogroup B meningococcal disease","author":"Feavers IM","year":"2017","unstructured":"Feavers IM, Maiden MCJ. Recent progress in the prevention of serogroup B meningococcal disease. Clin Vaccine Immunol: CVI. 2017;24(5).","journal-title":"Clin Vaccine Immunol: CVI."},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0906357"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6441a3"},{"key":"e_1_3_3_60_1","unstructured":"WHO Prequalified Vaccines. WHO: WHO."},{"key":"e_1_3_3_61_1","unstructured":"MenAfriVac [package insert]. Pune (India): Serum Institute of India; 2011. http:\/\/www.who.int\/immunization_standards\/vaccine_quality\/pq_197_menAconj_SII_PI_624-2.pdf."},{"key":"e_1_3_3_62_1","unstructured":"Menveo [package insert]. Cambridge (MA): Novartis Vaccines; 2013. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm201349.pdf."},{"key":"e_1_3_3_63_1","unstructured":"Trumenba [package insert]. Philadelphia (Pennsylvania): Pfizer; 2014. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm421139.pdf."},{"key":"e_1_3_3_64_1","unstructured":"Bexsero [package insert]. Research Triangle Park (North Carolina): GlaxoSmithKline; 2015. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm431447.pdf."},{"key":"e_1_3_3_65_1","unstructured":"Menactra [package insert]. Swiftwater (PA): Sanofi Pasteur; 2016. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm131170.pdf."},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.019"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00591-1"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.091"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.6.435"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197709292971302"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.6.861"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.37.1.205-208.1982"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.8"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.060"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00062-1"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1086\/515346"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00317-0"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00139-5"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2009.12.001"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(88)96117-8"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.159.10.907"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1136040"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7385.365"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27739"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-2380"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(09)60371-5"},{"key":"e_1_3_3_87_1","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Bilukha OO","year":"2005","unstructured":"Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1\u201321. PMID:15917737.","journal-title":"MMWR Recomm Rep."},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3321"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.032"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S962"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00207-09"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.147"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1143157"},{"key":"e_1_3_3_94_1","first-page":"1018","article-title":"Licensure of a meningococcal conjugate vaccine for children aged 2 through 10\u00a0years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease\u2013Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","year":"2011","unstructured":"Licensure of a meningococcal conjugate vaccine for children aged 2 through 10\u00a0years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease\u2013Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1018\u20139. PMID:21814165.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181fcb2bf"},{"key":"e_1_3_3_96_1","unstructured":"MenHibrix [package insert]. Rixensart (Belgium): GlaxoSmithKline; 2012. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm308577.pdf."},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ551"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61612-8"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91961-S"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.071"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00423-5"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1816"},{"key":"e_1_3_3_103_1","first-page":"608","article-title":"Use of Serogroup B Meningococcal Vaccines in Persons Aged >\/ = 10 Years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Folaranmi T","year":"2015","unstructured":"Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of Serogroup B Meningococcal Vaccines in Persons Aged >\/ = 10 Years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608\u201312. PMID:26068564.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.027"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70087-7"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31921-3"},{"key":"e_1_3_3_107_1","article-title":"(4CMenB) vaccine \u2013 the UK safety experience","author":"Bexsero Bryan P.","year":"2017","unstructured":"Bryan P. Bexsero (4CMenB) vaccine \u2013 the UK safety experience. 14th Congress of the EMGM, European Meningococcal and Haemophilus Disease Society. Prague, Czech Republic, 2017.","journal-title":"14th Congress of the EMGM, European Meningococcal and Haemophilus Disease Society"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piv064"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6619a6"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30314-0"},{"key":"e_1_3_3_111_1","volume-title":"Meeting of the Advisory Committee on Immunization Practices (ACIP)","author":"Meningococcal Vaccines","year":"2017","unstructured":"Meningococcal Vaccines. Meeting of the Advisory Committee on Immunization Practices (ACIP). Atlanta (GA): Centers for Disease Control and Prevention; 2017."},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60842-4"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60935-1"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix446"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix091"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.056"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22302"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.01340"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6444a6"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-160-1-201401070-00731"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0538-6"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a2520"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6543a3"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094136"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.214"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868100-00001"},{"key":"e_1_3_3_127_1","volume-title":"US Department of Health and Human Services, Food and Drug Administration","author":"Administration FaD","year":"2017","unstructured":"Administration FaD. Soliris product insert. In: US Department of Health and Human Services FaDA, ed. US Department of Health and Human Services, Food and Drug Administration. MD: Silver Spring; 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/125166lbl.pdf."},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2015.09.035"},{"key":"e_1_3_3_129_1","article-title":"World Health Organization position paper, Meningococcal A conjugate vaccine: Updated guidance, February 2015","author":"WHO","year":"2017","unstructured":"WHO. World Health Organization position paper, Meningococcal A conjugate vaccine: Updated guidance, February 2015. Vaccine. 2017 Jul 28. pii:S0264-410X(17)30971-4.","journal-title":"Vaccine"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.046"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1514866"},{"key":"e_1_3_3_132_1","unstructured":"CDC. Guidance for the Evaluation and Public Health Management of Suspected Outbreaks of Meningococcal Disease. 2017:1\u201320. https:\/\/www.cdc.gov\/meningococcal\/downloads\/meningococcal-outbreak-guidance.pdf."},{"key":"e_1_3_3_133_1","article-title":"Preparedness for and response to meningococcal outbreaks: preliminary results of a Canadian Immunization Research Network (CIRN) randomized controlled trial of two schedules of 4CMenB vaccine in adolescents and young adults","author":"Langley J.","year":"2017","unstructured":"Langley J. Preparedness for and response to meningococcal outbreaks: preliminary results of a Canadian Immunization Research Network (CIRN) randomized controlled trial of two schedules of 4CMenB vaccine in adolescents and young adults. Meningitis Research Foundation Conference. London, UK, 2017.","journal-title":"Meningitis Research Foundation Conference"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03502-9"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800058556"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.027"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6521a5"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix215"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1620971114"},{"key":"e_1_3_3_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31449-6"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.486-491.2006"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24129"},{"key":"e_1_3_3_143_1","article-title":"Impact of MenZB on the incidence of gonorrhoea and potential future implications for cost effectiveness of teenage meningococcal vaccination","author":"Paynter J","year":"2017","unstructured":"Paynter J. Impact of MenZB on the incidence of gonorrhoea and potential future implications for cost effectiveness of teenage meningococcal vaccination. Meningitis Research Foundation Conference. London, UK, 2017.","journal-title":"Meningitis Research Foundation Conference"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61572-X"},{"key":"e_1_3_3_145_1","first-page":"h308","article-title":"Do we need a new approach to making vaccine recommendations?","volume":"350","author":"Crowcroft NS","year":"2015","unstructured":"Crowcroft NS, Deeks SL, Upshur RE. Do we need a new approach to making vaccine recommendations? BMJ (Clinical research ed) 2015;350:h308. PMID:25637290.","journal-title":"BMJ (Clinical research ed)"},{"key":"e_1_3_3_146_1","article-title":"Progress on MenACWYX vaccine: phase 1 trial results","author":"LaForce M.","year":"2017","unstructured":"LaForce M. Progress on MenACWYX vaccine: phase 1 trial results. Meningitis Research Foundation Conference. London, UK, 2017.","journal-title":"Meningitis Research Foundation Conference"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000822"},{"key":"e_1_3_3_148_1","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines \u2014 Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","year":"2011","unstructured":"Updated recommendations for use of meningococcal conjugate vaccines \u2014 Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal wkly Rep. 2011;60:72\u20136. PMID:21270745.","journal-title":"MMWR Morb Mortal wkly Rep."}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2018.1451810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:23:14Z","timestamp":1772742194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2018.1451810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":147,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5,4]]}},"alternative-id":["10.1080\/21645515.2018.1451810"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2018.1451810","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}